Hydromorphone, liquid oral — Competitive Intelligence Brief

Hydromorphone, liquid oral (Hydromorphone, liquid oral) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic. Area: Pain Management.

phase 3 Opioid analgesic Mu opioid receptor Pain Management Small molecule

Target snapshot

Hydromorphone, liquid oral (Hydromorphone, liquid oral) — University of British Columbia. Hydromorphone is an opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and sedation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hydromorphone, liquid oral TARGET	Hydromorphone, liquid oral	University of British Columbia	phase 3	Opioid analgesic	Mu opioid receptor
NALBUPHINE HYDROCHLORIDE	NALBUPHINE HYDROCHLORIDE		marketed		kappa opioid receptors, mu opioid receptors	1979-01-01
Ketamine + methadone	Ketamine + methadone	Cedars-Sinai Medical Center	marketed	NMDA receptor antagonist + synthetic opioid agonist combination	NMDA receptor (ketamine); mu opioid receptor (methadone)
hydrocodone/APAP	hydrocodone/APAP	VA Office of Research and Development	marketed	Opioid analgesic combination	Mu opioid receptor (hydrocodone); COX inhibitor (acetaminophen)
PCM/Oxy1	PCM/Oxy1	Maastricht University Medical Center	marketed	Opioid analgesic combination	Mu opioid receptor (oxycodone); COX enzymes (paracetamol)
Bupivacaine-fentanyl elective group	Bupivacaine-fentanyl elective group	Conrad Arnfinn Bjørshol	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
Crushed ticagrelor, morphine,naloxone	Crushed ticagrelor, morphine,naloxone	Collegium Medicum w Bydgoszczy	marketed	Antiplatelet agent + opioid + opioid antagonist combination	P2Y12 receptor (ticagrelor); mu opioid receptor (morphine); opioid receptors (naloxone antagonism)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic class)

1. Alza Corporation, DE, USA · 3 drugs in this class
2. Labopharm Inc. · 3 drugs in this class
3. University of Rochester · 3 drugs in this class
4. Purdue Pharma LP · 3 drugs in this class
5. Institute of Child Health · 2 drugs in this class
6. London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · 2 drugs in this class
7. Fujian Cancer Hospital · 2 drugs in this class
8. Children's Hospital of Fudan University · 2 drugs in this class
9. AdventHealth · 2 drugs in this class
10. Danish University of Pharmaceutical Sciences · 2 drugs in this class